A Brief History of Oncternal Therapeutics, Inc. (ONCT)

Oncternal Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. The company was founded in 2013 and is headquartered in San Diego, California.

Some key points in the history of Oncternal Therapeutics, Inc. include:

• 2013: Oncternal Therapeutics, Inc. is founded with a mission to develop innovative cancer therapies targeting specific genetic mutations.
• 2016: The company initiates its first clinical trial for a novel small molecule inhibitor targeting a key pathway in cancer cells.
• 2018: Oncternal Therapeutics, Inc. completes a successful initial public offering (IPO) to raise funds for further development of its pipeline of oncology therapies.
• 2020: The company announces promising results from a Phase 2 clinical trial of its lead compound in patients with a rare form of cancer, leading to accelerated development and regulatory milestones.
• Present: Oncternal Therapeutics, Inc. continues to advance its pipeline of oncology therapies through strategic partnerships, clinical collaborations, and further research and development efforts.

Who Owns Oncternal Therapeutics, Inc. (ONCT)

Oncternal Therapeutics, Inc. (ONCT) is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies. The ownership of the company is broken down as follows:

• Insiders: Insiders own a significant portion of Oncternal Therapeutics, Inc. This includes executives, directors, and employees of the company.
• Institutional Investors: Institutional investors also have a stake in ONCT. These include large financial institutions, mutual funds, and other investment firms.
• Retail Investors: Retail investors, including individual shareholders, also own shares of Oncternal Therapeutics, Inc.
• Public Ownership: ONCT is a publicly traded company, meaning that shares are available for purchase on the stock market by any investor.

Oncternal Therapeutics, Inc. (ONCT) Mission Statement

Oncternal Therapeutics, Inc. is dedicated to improving the lives of patients with cancer by developing and commercializing novel therapies that target specific treatment challenges in oncology. Our mission is to bring hope to patients and advance the field of oncology through innovative research and development.

At Oncternal Therapeutics, we are committed to pushing the boundaries of scientific discovery to create transformative therapies that address unmet medical needs in cancer treatment. We believe in the power of collaboration and strive for excellence in everything we do.

• Empowering patients: We prioritize the needs of patients and strive to develop therapies that improve outcomes and quality of life.
• Scientific innovation: We invest in cutting-edge research to develop novel therapies that have the potential to revolutionize cancer treatment.
• Commitment to excellence: We hold ourselves to the highest standards of integrity, quality, and performance in all aspects of our work.
• Collaborative spirit: We value teamwork and partnerships with leading experts in the field to accelerate progress and achieve our mission.

How Oncternal Therapeutics, Inc. (ONCT) Works

Oncternal Therapeutics, Inc. (ONCT) is a clinical-stage biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. The company utilizes a multi-faceted approach to discover, develop, and commercialize novel drugs targeting specific types of cancer.

One of the key aspects of how ONCT works is through their targeted therapy programs. The company focuses on identifying genetic mutations and other abnormalities in cancer cells that can be targeted with specific drugs. This approach allows for more precise and effective treatments, minimizing side effects and improving patient outcomes.

ONCT also collaborates with leading research institutions and pharmaceutical companies to leverage their expertise and resources in drug development. By working with external partners, ONCT is able to accelerate the pace of their research and bring potential treatments to market more quickly.

• Research and Development: ONCT invests heavily in research and development to identify new drug targets and develop innovative therapies. Their team of scientists and researchers are constantly exploring new avenues for cancer treatment.
• Clinical Trials: ONCT conducts clinical trials to test the safety and efficacy of their drug candidates. These trials involve collaboration with healthcare providers and patients to gather data on the potential benefits of the treatments.
• Regulatory Approval: Once a drug candidate has shown promising results in clinical trials, ONCT seeks regulatory approval from agencies such as the FDA to bring the treatment to market. This process involves rigorous testing and evaluation to ensure the safety and effectiveness of the drug.

How Oncternal Therapeutics, Inc. (ONCT) Makes Money

Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies. The company generates revenue through a few key ways:

• Drug Development Partnerships: Oncternal Therapeutics collaborates with pharmaceutical companies to develop and commercialize new cancer therapies. These partnerships often involve upfront payments, milestone payments, and royalties on future sales.
• Licensing Agreements: The company also generates revenue through licensing agreements with other biopharmaceutical companies, granting them the rights to use Oncternal's technology or intellectual property in exchange for licensing fees or royalties.
• Clinical Trials: Oncternal Therapeutics conducts clinical trials to test the safety and efficacy of its drug candidates. The company may receive funding from government agencies, research organizations, or other companies to conduct these trials.
• Sales of Intellectual Property: Oncternal may generate revenue by selling or licensing its intellectual property, such as patents or proprietary technology, to other companies or research institutions.

Overall, Oncternal Therapeutics, Inc. utilizes a combination of partnerships, licensing agreements, clinical trials, and intellectual property sales to generate revenue and fund the development of new cancer therapies.